$LGVNR News
Last published 2w ago
- 2w agoLGVNLGVNRLongeveron Announces Engagement of Lucid Capital MarketsGlobeNewswireMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the "Company") (NASDAQ:LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore
- 2w agoLGVNLGVNRLongeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswireELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions As previously reported, the ELPIS II trial did not meet the
- 1mo agoLGVNLGVNRLongeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswireCompany Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction
- 2mo agoLGVNLGVNRLongeveron to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related
- 2mo agoLGVNLGVNRLongeveron Announces 1-for-10 Reverse Stock SplitGlobeNewswireMIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 2mo agoLGVNLGVNRIRDDERMLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerGlobeNewswireMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE)
- 3mo agoLGVNLGVNRLongeveron Announces 2026 Second Quarter Financial Results and Provides Business UpdateGlobeNewswireOn track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and
- 3mo agoLGVNLGVNRLongeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global CompetitionGlobeNewswireLongeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026
- 3mo agoLGVNLGVNRLongeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026GlobeNewswireMIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related
- 3mo agoLGVNLGVNRDeborah D. Ascheim, M.D. Elected to Longeveron Board of DirectorsGlobeNewswireMIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 4mo agoLGVNLGVNRLongeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s DiseaseGlobeNewswirePoster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled "Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed
- 4mo agoLGVNLGVNRLongeveron® Appoints Marie Washburn as Chief Financial OfficerGlobeNewswireMs. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy
- 3y agoLGVNLGVNRLong-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart AssociationGlobeNewswireExtended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing in Phase 2 ELPIS II
- 3y agoLGVNLGVNRLongeveron Issues Letter to StockholdersGlobeNewswireMIAMI, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic
- 3y agoLGVNLGVNRLong-term Survival Data from Longeveron's ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart AssociationGlobeNewswireMIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic
- 3y agoLGVNLGVNRLongeveron to Present at the 25th Annual H.C. Wainwright Global Investment ConferenceGlobeNewswireMIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic
- 3y agoLGVNLGVNRLongeveron to Participate in the 149th Annual National Investment Banking Association ConferenceGlobeNewswireMIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic
- 3y agoLGVNLGVNRLongeveron Rights Offering Subscription Period BeginsGlobeNewswireMIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic